Current status of gene therapy for breast cancer: Progress and challenges

Application of Clinical Genetics

Volumn 7, Issue , 2014, Pages 209-220

  McCrudden, Cian M ^a   McCarthy, Helen O ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Breast cancer; Clinical trial; Gene therapy; Nonviral

Indexed keywords

ALDESLEUKIN; ANTINEOPLASTIC AGENT; CYCLIN G1; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; DNA VACCINE; E1A PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUCYTOSINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HF 10; INTERLEUKIN 12; MOLGRAMOSTIM; ONCEPT; ONCOLYTIC HERPES VIRUS; PACLITAXEL; PELAREOREP; RETROVIRUS VECTOR; TALIMOGENE LAHERPAREPVEC; UNCLASSIFIED DRUG; ZR 75 1; ZYC 300;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; GENE; GENE DELETION; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS 1; HUMAN; ICP47 GENE; IMMUNE RESPONSE; MELANOMA; NONVIRAL GENE DELIVERY SYSTEM; ONCOLYTIC VIROTHERAPY; PARVOVIRIDAE; PHARMACOLOGICAL BLOCKING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REOVIRIDAE; RETROVIRUS; REVIEW; RNA INTERFERENCE; TREATMENT DURATION; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM;

EID: 84924760480     PISSN: None     EISSN: 1178704X     Source Type: Journal    
DOI: 10.2147/TACG.S54992     Document Type: Review

References (80)

1. Official Journal of the European Union. L 159: Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:159:0046:0094:en:PDF. Accessed October 15, 2014.
2. Kan O, Griffths L, Baban D, et al. Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene Ther. 2001;8(7):473–482.
3. Braybrooke J P, Slade A, Deplanque G, et al. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin Cancer Res. 2005;11(4):1512–1520.
4. Gordon EM, Levy J P, Reed RA, et al. Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ. Int J Oncol. 2008;33(4):665–675.
5. Gordon EM, Hall FL. Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an effcacious anti-cancer agent. Int J Oncol. 2010;36(6):1341–1353.
6. Hartkopf AD, Fehm T, Wallwiener D, Lauer UM. Oncolytic virotherapy of breast cancer. Gynecol Oncol. 2011;123(1):164–171.
7. Takakuwa H, Goshima F, Nozawa N, et al. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch Virol. 2003;148(4):813–825.
8. Teshigahara O, Goshima F, Takao K, et al. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10. J Surg Oncol. 2004;85(1):42–47.
9. Kimata H, Imai T, Kikumori T, et al. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann Surg Oncol. 2006;13(8):1078–1084.
10. Sahin TT, Kasuya H, Nomura N, et al. Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer. Cancer Gene Ther. 2012;19(4): 229–237.
11. Russell SJ, Federspiel MJ, Peng K W, et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc. 2014;89(7):926–933.
12. Hu JC, Coffn RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12(22):6737–6747.
13. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292–303.
14. Guffey MB, Parker JN, Luckett WS Jr, et al. Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Ther. 2007;14(1):45–56.
15. Papanastassiou V, Rampling R, Fraser M, et al. The potential for efficacy of the modifed (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther. 2002;9(6):398–406.
16. MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet. 2001;357(9255): 525–526.
17. Cody JJ, Scaturro P, Cantor AB, Yancey Gillespie G, Parker JN, Markert JM. Preclinical evaluation of oncolytic deltagamma(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases. Int J Breast Cancer. 2012;2012:628697.
18. Colombo M P, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13(2):155–168.
19. Siegl G. Biology and pathogenicity of autonomous parvoviruses. In: Berns KI, editor. The Parvoviruses. 1st ed. New York: Springer US; 1984:264–297.
20. Cornelis JJ, Chen YQ, Spruyt N, et al. Susceptibility of human cells to killing by the parvoviruses H-1 and minute virus of mice correlates with viral transcription. J Virol. 1990;64(6):2537–2544.
21. Sieben M, Schafer P, Dinsart C, Galle PR, Moehler M. Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1. Int J Cancer. 2013;132(11):2548–2556.
22. Muharram G, Le Rhun E, Loison I, et al. Parvovirus H-1 induces cyto-pathic effects in breast carcinoma-derived cultures. Breast Cancer Res Treat. 2010;121(1):23–33.
23. Angelova AL, Aprahamian M, Grekova S P, et al. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of onco-lytic parvovirus H-1PV. Clin Cancer Res. 2009;15(2):511–519.
24. Enderlin M, Kleinmann E V, Struyf S, et al. TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Ther. 2009;16(2):149–160.
25. Norman KL, Coffey MC, Hirasawa K, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther. 2002;13(5):641–652.
26. Gollamudi R, Ghalib MH, Desai KK, et al. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs. 2010;28(5):641–649.
27. Vidal L, Pandha HS, Yap TA, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res. 2008;14(21):7127–7137.
28. Harrington KJ, Karapanagiotou EM, Roulstone V, et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res. 2010;16(11):3067–3077.
29. Nanni P, Gatta V, Menotti L, et al. Preclinical therapy of disseminated HER-2(+) ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. PLoS Pathog. 2013;9(1):e1003155.
30. Cody JJ, Markert JM, Hurst DR. Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells. PLoS One. 2014;9(3):e92919.
31. Walther W, Siegel R, Kobelt D, et al. Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer. Clin Cancer Res. 2008;14(22):7545–7553.
32. Shibata MA, Ito Y, Morimoto J, Kusakabe K, Yoshinaka R, Otsuki Y. In vivo electrogene transfer of interleukin-12 inhibits tumor growth and lymph node and lung metastases in mouse mammary carcinomas. J Gene Med. 2006;8(3):335–352.
33. Miyata K, Nishiyama N, Kataoka K. Rational design of smart supra-molecular assemblies for gene delivery: chemical challenges in the creation of artifcial viruses. Chem Soc Rev. 2012;41(7):2562–2574.
34. Yo o GH, Hung MC, Lopez-Berestein G, et al. Phase I trial of intratu-moral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res. 2001;7(5):1237–1245.
35. Hortobagyi GN, Ueno NT, Xia W, et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol. 2001;19(14): 3422–3433.
36. Gribben JG, Ryan D P, Boyajian R, et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res. 2005;11(12):4430–4436.
37. McCrudden C, McCarthy H. Cancer gene therapy – key biological concepts in the design of multifunctional non-viral delivery systems. In: Molina FM, editor. Cancer Gene Therapy. 1st ed. Rijeka, Croatia: InTech; 2013:213–235.
38. Robson T, Hirst DG. Transcriptional targeting in cancer gene therapy. J Biomed Biotechnol. 2003;2003(2):110–137.
39. Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. 2014;15(2): e58–e68.
40. McCarthy HO, Coulter JA, Worthington J, Robson T, Hirst DG. Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specifcity for hormone refractory prostate cancer. J Gene Med. 2007;9(6):511–520.
41. Coulter JA, Page NL, Worthington J, Robson T, Hirst DG, McCarthy HO. Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer. J Gene Med. 2010;12(9):755–765.
42. Pandha HS, Martin LA, Rigg A, et al. Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol. 1999;17(7):2180–2189.
43. Garg H, Salcedo R, Trinchieri G, Blumenthal R. Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax. Cancer Gene Ther. 2010;17(3):155–163.
44. Sadeqzadeh E, Rahbarizadeh F, Ahmadvand D, Rasaee MJ, Parhamifar L, Moghimi SM. Combined MUC1-specifc nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells. J Control Release. 2011;156(1):85–91.
45. Yun HJ, Cho YH, Moon Y, et al. Transcriptional targeting of gene expression in breast cancer by the promoters of protein regulator of cytokinesis 1 and ribonuclease reductase 2. Exp Mol Med. 2008;40(3): 345–353.
46. Yan C, Wen-Chao L, Hong-Yan Q, Rui Z, Wei-Lin J, Hua H. A new targeting approach for breast cancer gene therapy using the human fatty acid synthase promoter. Acta Oncol. 2007;46(6):773–781.
47. Anderson LM, Krotz S, Weitzman SA, Thimmapaya B. Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach. Cancer Gene Ther. 2000;7(6):845–852.
48. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs shRNA: similarities and differences. Adv Drug Deliv Rev. 2009;61(9):746–759.
49. Yang F, Huang W, Li Y, et al. Anti-tumor effects in mice induced by survivin-targeted siRNA delivered through polysaccharide nanoparticles. Biomaterials. 2013;34(22):5689–5699.
50. Gao Y, Chen L, Zhang Z, Chen Y, Li Y. Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles. Biomaterials. 2011;32(6):1738–1747.
51. Wang Y, Gao S, Ye WH, Yoon HS, Yang YY. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater. 2006;5(10):791–796.
52. Janat-Amsbury MM, Yockman J W, Lee M, et al. Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model. Mol Ther. 2004;9(6):829–836.
53. Okamoto A, Asai T, Kato H, et al. Antibody-modified lipid nano-particles for selective delivery of siRNA to tumors expressing membrane-anchored form of HB-EGF. Biochem Biophys Res Commun. 2014;449(4):460–465.
54. Ding Y, Wang Y, Zhou J, et al. Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis. Biomaterials. 2014;35(25):7214–7227.
55. Feng Q, Yu MZ, Wang JC, et al. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles. Biomaterials. 2014;35(18):5028–5038.
56. Rejeeth C, Kannan S. P53 gene therapy of human breast carcinoma: using a transferrin-modifed silica nanoparticles. Breast Cancer. Epub May 4, 2014.
57. Mao CQ, Du JZ, Sun TM, et al. A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy. Biomaterials. 2011;32(11): 3124–3133.
58. Medina-Kauwe LK, Maguire M, Kasahara N, Kedes L. Nonviral gene delivery to human breast cancer cells by targeted Ad5 penton proteins. Gene Ther. 2001;8(23):1753–1761.
59. Mangipudi SS, Canine B F, Wang Y, Hatef A. Development of a genetically engineered biomimetic vector for targeted gene transfer to breast cancer cells. Mol Pharm. 2009;6(4):1100–1109.
60. McCarthy HO, Zholobenko AV, Wang Y, et al. Evaluation of a multifunctional nanocarrier for targeted breast cancer iNOS gene therapy. Int J Pharm. 2011;405(1–2):196–202.
61. Jeyarajan S, Xavier J, Rao NM, Gopal V. Plasmid DNA delivery into MDA-MB-453 cells mediated by recombinant Her-NLS fusion protein. Int J Nanomedicine. 2010;5:725–733.
62. Soltani F, Sankian M, Hatef A, Ramezani M. Development of a novel histone H1-based recombinant fusion peptide for targeted non-viral gene delivery. Int J Pharm. 2013;441(1–2):307–315.
63. Dou S, Ya o YD, Yang XZ, et al. Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy. J Control Release. 2012;161(3):875–883.
64. Govindarajan S, Sivakumar J, Garimidi P, et al. Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-affbody bioconjugate. Biomaterials. 2012;33(8):2570–2582.
65. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature. 1992;356(6365): 152–154.
66. Ulmer JB, Fu TM, Deck RR, et al. Protective CD4+ and CD8+ T cells against infuenza virus induced by vaccination with nucleoprotein DNA. J Virol. 1998;72(7):5648–5653.
67. Grosenbaugh DA, Leard AT, Bergman PJ, et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res. 2011;72(12):1631–1638.
68. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14): 1273–1283.
69. Chung MA, Luo Y, O’Donnell M, et al. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine. Cancer Res. 2003;63(6):1280–1287.
70. Hodge J W. Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol Immunother. 1996;43(3):127–134.
71. Watson MA, Dintzis S, Darrow CM, et al. Mammaglobin expression in primary, metastatic, and occult breast cancer. Cancer Res. 1999;59(13):3028–3031.
72. Bednarek AK, Sahin A, Brenner AJ, Johnston DA, Aldaz CM. Analysis of telomerase activity levels in breast cancer: positive detection at the in situ breast carcinoma stage. Clin Cancer Res. 1997;3(1):11–16.
73. De Giovanni C, Nicoletti G, Quaglino E, et al. Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast Cancer Res. 2014;16(1):R10.
74. Norell H, Poschke I, Charo J, et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med. 2010;8:53.
75. Narayanan K, Jaramillo A, Benshoff ND, et al. Response of established human breast tumors to vaccination with mammaglobin-A cDNA. J Natl Cancer Inst. 2004;96(18):1388–1396.
76. Tiriveedhi V, Fleming T P, Goedegebuure PS, et al. Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells. Breast Cancer Res Treat. 2013;138(1):109–118.
77. Endmann A, Oswald D, Riede O, et al. Combination of MIDGE-Th1 DNA vaccines with the cationic lipid SAINT-18: studies on formulation, biodistribution and vector clearance. Vaccine. 2014;32(27):3460–3467.
78. Mairhofer J, Cserjan-Puschmann M, Striedner G, Nobauer K, Razzazi-Fazeli E, Grabherr R. Marker-free plasmids for gene therapeutic applications – lack of antibiotic resistance gene substantially improves the manufacturing process. J Biotechnol. 2010;146(3):130–137.
79. Walters AA, Kinnear E, Shattock RJ, et al. Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines. Gene Ther. 2014;21(7):645–652.
80. Canine B F, Wang Y, Hatef A. Biosynthesis and characterization of a novel genetically engineered polymer for targeted gene transfer to cancer cells. J Control Release. 2009;138(3):188–196.